Ajanta Pharma declines after muted Q4 performance

10 May 2022 , 03:30 PM

On the segmental front, revenue from Exports was Rs 616 crore (up 17% YoY) while that from the Domestic business was Rs 245 crore (up 13% YoY) during the quarter. Total expenses rose by 32% YoY to Rs 701 crore during the quarter. During Q4 FY22, R&D expenses were Rs 59 crore, which is 7% of revenue from operations. R&D expenses were R. 39 crore in Q4 FY21. EBITDA declined by 20% to Rs 207 crore in Q4 FY22 from Rs 259 crore in Q4 FY21. EBITDA margin was 24% in Q4 FY22 as against 34% in Q4 FY21. Profit before tax in Q4 FY22 stood at Rs 198 crore, down by 14% from Rs 229 crore in Q4 FY21. The company reported 9% increase in consolidated net profit to Rs 713 crore on a 16% rise in revenue from operations to Rs 3,341 crore in FY22 over FY21. The board of directors has considered and approved the bonus issue of equity shares in the proportion of one equity share for every two equity share held by the shareholders of the company as on the record date. Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Powered by Capital Market – Live News